Ignite Creation Date:
2025-12-25 @ 1:34 AM
Ignite Modification Date:
2026-05-20 @ 6:57 PM
Study NCT ID:
NCT00667394
Status:
COMPLETED
Last Update Posted:
2015-11-05
First Post:
2008-04-25
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
080101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None